BACKGROUND: The incidence of subclinical cardiotoxicity following anthracycline treatment
for childhood cancer varies according to the method used for its detection. The aim of the …

Background Exposure to anthracyclines (ANT) during childhood represents a high risk for
development of late cardiotoxicity. Cardiotoxicity is usually detected only when clinical …

Objective Anthracyclines are well established as highly efficacious antineoplastic agents for
childhood malignancy, but they frequently cause dose-related cardiotoxicity. For this reason …

Background Anthracyclines are effective anticancer drugs for childhood cancer with dose‐
limiting cardiotoxicity. Children who have received anthracyclines thus need periodical …

Background Anthracycline‐induced cardiotoxicity can cause serious health problems for an
increasing number of survivors of childhood malignancies. The aims of this study were to …

Background Anthracyclines are widely used in the treatment of pediatric cancer but their use
is associated with cardiotoxicity. The cardiotoxic effect may become clinically apparent many …

Background: The use of anthracyclines in treatment of cancer is limited by cardiotoxicity of
these compounds and may lead to heart failure. Therefore monitoring of cardiac function is …

Background Anthracyclines (AC) are useful antineoplastic agents, whose utility is limited by
progressive cardiotoxicity. Our purpose was to evaluate plasma B‐type natriuretic peptide …

The aim of this study was to evaluate N-terminal probrain natriuretic peptides (NT-pro-BNP),
cardiac troponin T, and creatinine kinase, MB isoenzyme (CK-MB) in the determination of …

Background Serum concentrations of N-terminal natriuretic pro-brain natriuretic peptide (NT-
proBNP) correlate well with the severity of cardiac disease in children and adults. There are …